Abilify (aripiprazole) is the first antipsychotic approved for major depressive disorder
January 2008
Abilify (aripiprazole) is the first antipsychotic approved for major depressive disorder...not just bipolar disorder.
It'll be added to antidepressants to augment their effects.
More than half of patients still have symptoms after starting an antidepressant. If symptoms persist after 4 to 8 weeks, encourage switching to another antidepressant...combining antidepressants...or adding a different type of drug to boost efficacy.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote